All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Janssen Pharmaceuticals Inc. has agreed to pay up to $780 million in up-front, milestone payments and R&D funding for exclusive rights to antiviral conjugates to be developed by Cidara Therapeutics Inc. for the prevention and treatment of seasonal and pandemic influenza.